Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03699475
Title Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE)
Acronym THRIVE
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bellicum Pharmaceuticals
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.